Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847538 | 0.89 | KMT2A (0.43) | SERPINE1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL3222423 | 0.86 | HDAC8 (0.50) | KMT2AMEN1LMNASMN1; SMN2HDAC8 | |
| SCHEMBL13267390 | 0.83 | SERPINE1 (0.53) | SERPINE1HDAC8HDAC6HDAC1PRKAB2 | |
| SCHEMBL469036 | 0.82 | HDAC8 (0.61) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL14507812 | 0.81 | SERPINE1 (0.49) | SERPINE1SMN1; SMN2HDAC8HDAC6HDAC1 | |
| SCHEMBL6822864 | 0.81 | HDAC8 (0.59) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12337677 | 0.81 | HDAC8 (0.59) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6822733 | 0.81 | HDAC8 (0.59) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL18702957 | 0.81 | LMNA (0.43) | KMT2AMEN1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL15081033 | 0.81 | HDAC8 (0.59) | KMT2AMEN1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | SERPINE1 3511/4885KMT2A 2162/4885MEN1 2784/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SERPINE1 3511/4885KMT2A 2162/4885MEN1 2784/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SERPINE1 3511/4885KMT2A 2162/4885MEN1 2784/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | SERPINE1 886/4885KMT2A 2503/4885MEN1 2706/4885 |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | SERPINE1 926/4885KMT2A 1042/4885MEN1 3144/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SERPINE1 3486/4885KMT2A 1907/4885MEN1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.